A recent study found that the hepatitis C virus decays during treatment with telaprevir faster in the bloodstream than it does in the liver, a discovery that could help pinpoint how long a patient needs to take medicine to rid the virus from the body.
“We found that HCV RNA decay in the liver lagged behind that in the
peripheral blood, which has implications for how long the virus may
persist in the body and the possible duration of treatment needed,”
Andrew Talal, MD, said in the statement. Higher levels of telaprevir were also found
in blood when compared to the liver.
Before this study, there was no precise definition of treatment duration
based upon serial measurements of the virus in the liver, according to